



# HHS Public Access

Author manuscript

*Nat Neurosci.* Author manuscript; available in PMC 2016 March 01.

Published in final edited form as:

*Nat Neurosci.* 2015 March ; 18(3): 367–372. doi:10.1038/nn.3947.

## Molecular mechanisms of epilepsy

**Kevin Staley**

Neurology Department Massachusetts General Hospital Harvard Medical School  
Staley.kevin@MGH.Harvard.edu

### Abstract

Decades of experimental work have established an imbalance of excitation and inhibition as the leading mechanism of the transition from normal brain function to seizure. In epilepsy, these transitions are rare and abrupt. Transition processes incorporating positive feedback, such as activity-dependent disinhibition, could provide these unique timing features. A rapidly expanding array of genetic etiologies will help delineate the molecular mechanism(s). This delineation will entail quite a bit of cell biology. The genes discovered to date are currently more remarkable for their diversity than their similarities.

### Introduction

Epileptic activity can be induced acutely by blocking synaptic and voltage-gated inhibitory conductances<sup>1, 2</sup>, or by activating synaptic and voltage-gated excitatory conductances<sup>3</sup>. Seizures are blocked by the opposite manipulations: increasing inhibition<sup>4</sup> or decreasing excitation<sup>5</sup>. Several decades of these types of pharmacological experiments have established the idea that an imbalance between inhibitory and excitatory conductances leads to seizures (i.e. is ictogenic) in otherwise normal brain tissue<sup>6</sup>. This imbalance is most clearly embodied clinically in toxic exposures such as domoic acid, which activates excitatory GluK1 glutamate receptors, or by overdoses of theophylline, which blocks the inhibitory adenosine A1 receptor<sup>7, 8</sup>. In these cases, immediate, repeated, and medically intractable seizure activity is induced in otherwise normal subjects. An imbalance between excitation and inhibition is thus a validated ictogenic mechanism. Difficulties arise in extending this mechanism to epileptogenesis, that is, as a mechanism that creates a persistent increase in the probability of spontaneous seizures.

Chronic epilepsy rather than toxic exposure is responsible for the vast majority of seizures in human patients, and this condition requires an expansion of the theory of an imbalance between inhibitory and excitatory conductances. This expansion is needed for two reasons. First, unlike the acute exposures, the timing of seizures in chronic epilepsy is unpredictable and seizures are relatively rare, representing much less than 1 % of the total brain activity except in the most severe epileptic encephalopathies<sup>9</sup>. Thus in chronic epilepsy, not only is an ictogenic mechanism required, but this mechanism or an additional mechanism must also explain the timing of episodic transitions from normal activity to seizures.

The second area of difficulty in applying a theory of imbalanced inhibition and excitation is that the etiology of epilepsy does not usually suggest such an imbalance. In epilepsies arising from a genetic cause, analyses of the genetic etiology have occasionally found causal

loss-of-functions mutations in inhibitory conductances<sup>10</sup>, but loss-of-function mutations are also found in several excitatory conductances<sup>11, 12</sup>, and the majority of causal mutations involve loss of function of genes that do not directly alter the balance of inhibition and excitation<sup>13</sup>. Commercially available diagnostic genetic sequencing services now feature panels of several hundred genes that have been associated with epilepsy. Most of these genes do not encode membrane conductances. This is in line with the intermittent nature of seizures described above; genetic abnormalities that compromise important inhibitory conductances would be expected to continuously alter brain function. Thus such mutations are most frequently associated with severe epileptic encephalopathies, in which there are no normal epochs of brain activity, and frequent seizures<sup>14, 15, 16</sup>.

In the acquired epilepsies, spontaneous seizures begin after injury to a normal brain as a consequence of trauma, stroke, infection or status epilepticus. Steady-state imbalances in excitation vs. inhibition are difficult to demonstrate in established animal models of acquired epilepsy. Damage to inhibitory neurons is compensated by increases in GABAergic synaptogenesis before the onset of seizures in the pilocarpine model<sup>17</sup>. Compensatory glutamatergic synaptogenesis also occurs<sup>18</sup>, but steady-state network imbalances in excitation vs. inhibition are not apparent in experimental and human epilepsy<sup>19</sup>.

Thus we need to expand the experimentally-derived idea of time-invariant ictogenic imbalances between inhibition and excitation to encompass both the timing of seizures and the wide variety of etiologies of human epilepsy.

## Timing of seizures

One explanation for the timing of seizures in chronic epilepsy is an episodic shift in the balance of inhibition and excitation, which begs the question as to the mechanisms of the episodic shifts in this balance. Other possibilities include seizure mechanisms that are of low probability, for example circular or reentrant activity that can occur only in network states that exist very rarely. The probability of entry into a seizure under such conditions may not be a direct consequence of the molecular mechanism of ictogenesis. For example, in autosomal dominant nocturnal frontal lobe epilepsy (ADFNLE) arising from gain-of-function mutations in a nicotinic cholinergic receptor, seizures only occur in non rapid eye movement (nonREM) sleep<sup>20</sup> (Ferini-Strambi et al. 2012). Thus network (brain) states may be an important determinant of seizure timing. Network states that are less probable than nonREM sleep may be responsible for proportionately lower frequencies of seizures: for example, in catamenial epilepsy, seizures occur predominantly at specific stages of the menstrual cycle<sup>21</sup>. While global brain states may help explain changes in seizure probability, they do not directly explain seizure timing. For both ADFNLE and catamenial epilepsy, most of the at-risk periods are characterized by the absence of seizure activity. Thus in the high-risk periods, additional mechanisms must induce further, ictogenic alterations of the balance of inhibition and excitation.

Unpredictable and low-frequency events can be readily generated by low-probability state transitions in nonlinear systems<sup>22, 23</sup>. While this body of analysis does not lend itself to elucidating molecular mechanisms, it does emphasize that the improbable state itself must

be at least temporarily stable. If the ictal state were not stable, there would be continual exits at random times from the seizure state, which generally does not occur: both experimental and human seizure durations are stereotyped, ranging from seconds for absence epilepsy to one or two minutes for primary and secondarily generalized tonic clonic seizures.

One way to explain both low-probability ictal transitions and ictal stability is to incorporate positive feedback into the ictogenic mechanism (Figure). For example, if transient imbalances in inhibition and excitation engendered further imbalance, this imbalance could occasionally build to the point of engendering a seizure. Activity-dependent reductions in the efficacy of neuronal inhibition, or activity-dependent disinhibition, comprises one such mechanism, or set of mechanisms<sup>24, 25, 26</sup>. If disinhibition occurred only at extremes of local network activity, then the probability of ictal transition would depend on the probability of that exceptional level of local network activity. Presumably these levels of activity could occur over the same range of probabilities as those characterizing spontaneous seizures. Once a seizure was induced by an activity-dependent reduction in the balance of inhibition to excitation, the seizure itself could continue to produce activity levels that were sufficient to suppress inhibition or enhance excitation, providing the necessary positive feedback to sustain the seizure.

### **Molecular mechanisms of activity-dependent shifts in the balance of inhibition and excitation**

One way to delimit candidate ictogenic mechanisms is to consider the duration of the epochs of elevated network activity that lead to seizures. Some candidate mechanisms can be excluded if we assume that the ictogenic mechanism must operate on the time scale relevant to the epoch of increased activity. Unfortunately, we don't really know how long these high-activity epochs might be. Clues include induction of seizures in experimental animals undergoing kindling<sup>27</sup>, and in patients undergoing electroshock treatment<sup>28</sup>; for such subjects, stimuli of a few seconds are sufficient to engender seizures. The duration of these stimuli represents the lower bound of epoch duration, because the applied stimuli synchronously activate many afferents, and such synchrony is unlikely to be engendered by physiological activity.

On a time scale of seconds, short-term synaptic plasticity could be a relevant mechanism of ictogenesis. Potentially ictogenic mechanisms of short-term synaptic plasticity include depression at inhibitory GABAergic synapses onto principal neurons<sup>24</sup>, and depression of glutamatergic synapses onto inhibitory neurons<sup>29</sup>, as well as facilitation of glutamatergic synapses between principal cells<sup>30</sup>, and facilitation of GABAergic inhibitory synapses onto inhibitory interneurons<sup>31</sup>. In short, either depression or facilitation, with loci at either GABAergic or glutamatergic synapses, could be proconvulsant, depending on the type of postsynaptic neuron. Neurotransmitter vesicle fusion with the presynaptic membrane requires the coordinate activity of a set of proteins subserving docking, priming, and fusion of the vesicles as well as calcium entry, sensing, and export<sup>32</sup>. Sustained fusion of neurotransmitter vesicles with the presynaptic membrane requires efficient neurotransmitter and vesicle recycling. Mutations in many of these presynaptic proteins have been demonstrated to be associated with epilepsy<sup>33, 34</sup>, whereas the anticonvulsants pregabalin

and levetiracetam interact with presynaptic calcium channels and docking proteins<sup>35</sup>. While these findings support the idea that abnormal short-term synaptic plasticity could underlie ictogenesis, it has not yet been demonstrated that abnormal short-term synaptic plasticity is necessary or sufficient to engender seizures or epilepsy<sup>36</sup>.

Postsynaptic mechanisms of synaptic plasticity acting on slightly longer time scales that are still likely to be relevant to epochs of increased network activity include include neurotransmitter reuptake, receptor desensitization, receptor membrane trafficking, and post-translational modifications of receptor subunits affecting transmitter affinity and channel gating. Mutations in proteins subserving some of these functions have been associated with epilepsy. For example epilepsy is engendered by mutations in the gene encoding for the stargazin member of the transmembrane AMPA receptor regulatory protein (TARP) family that modulates many aspects of AMPA-type glutamate receptor subunit membrane trafficking<sup>37, 38</sup> as well as by mutations in genes encoding for the LGI1 / ADAM22 proteins that link stargazin to the post synaptic density<sup>39</sup>. Some of these mechanisms, such as membrane trafficking of NMDA and GABA<sub>A</sub> receptors, have been implicated in the pathological prolongation of seizure activity initiated in normal animals by chemical or electrical stimulation<sup>40, 41</sup>. Intracellular signaling networks may participate in these activity-dependent shifts in the balance of excitation and inhibition<sup>42, 43</sup>.

Collectively the epileptogenic mutations in pre and postsynaptic proteins support the idea that functional shifts in the balance of inhibition vs. excitation arising from abnormal synaptic plasticity could transform high-normal levels of network activity into ictal activity. Another prominent mechanism of activity-dependent disinhibition involves dysregulation of ionic concentrations in the intra and extracellular spaces. Ions that have been implicated in activity-dependent ictogenesis include potassium, calcium, protons, and chloride<sup>44, 45, 46, 47</sup>. The relevant proteins involved in ionic homeostasis are broadly distributed in the brain, and include transmembrane channels and transporters in the membranes of the neuronal cytoplasm and subcellular organelles. Mutations in many of the genes encoding these proteins have been associated with epilepsy<sup>33, 15, 48</sup>. A great deal of experimental work has gone into testing the idea that activity-dependent shifts in ion concentrations contributes to ictogenesis. For example, tetanic stimulation of afferents as well as chemically induced seizure activity results in increases in  $K^+_o$  as potassium efflux overwhelms the ability of NaKATPase to maintain the appropriate cation gradients<sup>46</sup>. The increase in  $K^+_o$  shifts the potassium reversal potential to depolarized values, so that the resting membrane potential of neurons and cotransport of other ions is compromised. Similarly, large influxes of  $Ca^{2+}$  through voltage and ligand-gated conductances overwhelms the capacity for restorative calcium transport, resulting in reductions in extracellular calcium<sup>49, 50</sup>, altering both neurotransmitter release probability and the magnitude of calcium-dependent potassium conductances.

Prolonged activation of inhibitory GABAergic conductances can also degrade inhibition as a consequence of excitatory shifts in the GABA<sub>A</sub> reversal potential. The GABA receptor is permeable to chloride and bicarbonate, although under most circumstances the higher concentration and permeability of chloride make it the dominant charge carrier<sup>51</sup>. When high levels of GABAergic synaptic activity are sustained for periods on the order of one

second, the chloride flux through the GABA<sub>A</sub> receptor channel overwhelms the transport capacity of the cation-chloride cotransporters that maintain the steady-state transmembrane chloride gradients<sup>52, 53</sup>. This is due to the finite maximum velocity of the transporters as well as the finite velocity of NaKATPase, which maintains the appropriate driving forces for the cations whose diffusion provides the energy for chloride cotransport<sup>54</sup>. Under these circumstances, chloride becomes relatively passively distributed, so that the driving force for net ion movement through the GABA<sub>A</sub> channel is largely due to bicarbonate. The bicarbonate gradient does not degrade with activity because the free diffusion of CO<sub>2</sub> across the membrane and subsequent hydration/rehydration via carbonic anhydrase provides a strong buffer for the bicarbonate concentration. Free CO<sub>2</sub> diffusion keeps the bicarbonate approximately symmetrically distributed on both sides of the membrane, so that bicarbonate currents reverse near 0 mV. Thus the shift to net bicarbonate flux causes the GABA conductance to become very strongly depolarizing, so that instead of inhibition, GABAergic circuits subserve excitation as long as the GABA conductance is in excess of cotransport capacity<sup>52, 53, 55</sup>.

The activity-dependent synaptic and ionic mechanisms of disinhibition described above can result in ictal activity in normal tissue subject to sufficiently prolonged synchronous input in vivo and in vitro<sup>56, 57</sup>. Presumably, normal subjects do not experience seizures because the activity-dependent changes in synapses and ion concentrations do not cross the threshold needed to generate a self-reinforcing, positive feedback cycle of increased activity, disinhibition, and consequent further increases in activity. However, after injury a number of changes may make such cycles more probable. In the undercut model of post-traumatic epilepsy, NaKATPase levels and cotransport capacity are diminished, rendering ion concentrations less stable<sup>58</sup>. Loss of function mutations in NaKATPase are associated with epilepsy<sup>59</sup> and pharmacological reductions in NaKATPase activity engenders seizure activity in normal tissue<sup>60</sup>, supporting the idea that degradations in ionic homeostasis during periods of increased network activity is a key mechanism of ictogenesis.

### Setting the stage for activity-dependent shifts in the I/E balance

If rare, high levels of network activity create positive feedback cycles that reduce the balance of inhibition and excitation, why isn't everyone epileptic? Has the preceding discussion simply described the processes underlying the generalization of seizures, rather than ictogenesis? These questions suggest two possibilities: epilepsy may arise from uniquely high levels of network activity, or from unique vulnerabilities to activity-dependent shifts in the balance of inhibition to excitation. In the preceding section we focused on unique vulnerabilities to high-normal levels of synaptic activity. In this section, we consider mechanisms that may lead to uniquely high levels of network activity.

High, ictogenic levels of network activity could occur more readily in circuits with abnormal feedback due to cortical dysgenesis or the compensatory rewiring that occurs after brain injury. These circuit alterations are discussed in detail elsewhere in this issue. Here we consider the molecular mechanisms that might drive the formation of such an imbalanced circuit. A number of mutations in the PI3K / IGF / mTOR pathway have been reported in association with brain malformations that are strongly associated with epilepsy, including

focal cortical dysplasias, the gliotic tubers of tuberous sclerosis, and hemimegalencephaly<sup>61, 62</sup>. The mTOR cascade is an important anabolic cellular signaling pathway that is activated by growth factors such as IGF as well as abundance of metabolic substrates. Activation of this pathway may be a necessary step in the outgrowth of afferent and efferent neural processes<sup>63, 64</sup>, so that over-activation of the mTOR pathway may lead to unnecessary neuronal connectivity and epilepsy. Supporting this hypothesis is the more robust repression of seizure activity by mTOR inhibitors early in development<sup>65, 63</sup> when process outgrowth may be more active and potentially rate-limited by substrate availability, making synaptogenesis sensitive to anabolic cues, vs. more modest effects observed in the mature brain in which process outgrowth is much more limited<sup>66</sup>.

The condition of a sufficiently anabolic state is perhaps the most basic limitation on the development of synaptic connectivity, which is further influenced by a wide variety of cues that vary with location, cell type, and developmental stage. Accordingly, epileptic circuitry can be engendered by a host of defects that affect neuronal migration<sup>61</sup>, process outgrowth<sup>67</sup> and synaptic plasticity<sup>68, 69, 70</sup>. For example, the protein product of ARX, or aristaless related homeobox gene, is a transcription factor that is an important determinant of neuronal migration. ARX mutations have been associated with failure of interneuron migration to their proper cortical target<sup>71</sup>. If a population of interneurons do not successfully complete tangential migration to a cortical circuit due to mutations in ARX, it is likely that the cortical circuit will be chronically mis-inhibited. This is because the populations of interneurons that *do* successfully innervate this area may not be able to assume all of the duties of the interneurons that didn't reach their target. The successfully migrating neurons may not have the appropriate firing properties, calcium buffers, or synaptic connectivity to successfully inhibit the network under all circumstances<sup>72</sup>. Such a network would be prone to disinhibition during peaks of network activity, engendering seizures either in the mis-inhibited circuit itself, or in the downstream synaptic targets of the mis-inhibited circuit. A host of signals regulate interneuron differentiation and migration<sup>73</sup>, and mutations in many of these signals are associated with severe epileptic encephalopathies<sup>14</sup>.

Interneurons may migrate to the right place in time to form the proper connections, but still be unable to provide the levels of negative feedback necessary to prevent ictogenic levels of network activity. An example of this may be the autosomal dominant SCN1A sodium channel mutations that underlies Dravet syndrome, a serious epileptic encephalopathy of childhood. A leading mechanistic hypothesis is that haploinsufficiency of the SCN1A gene results in lower densities of the Nav1.1 sodium channel, and that the concomitant reduction in sodium currents and action potential firing causes the most significant functional compromise in fast-firing GABAergic basket cells<sup>11</sup>. In this scheme, basket cell function is sufficient to regulate network activity under all but the higher range of normal network activity.

## Neuronal homeostasis

There are many epilepsies associated with neuronal loss, either due to brain injury or to degenerative disorders. The strategies that neurons use to rewire circuits are even less well



understood than the strategies used to wire the original circuits during development. Neuronal homeostasis refers to the process by which neurons regulate their excitability. Thus in conditions that engender excess activity, neurons downregulate excitatory conductances and upregulate inhibitory conductances; the reverse is true under conditions of chronically reduced excitation<sup>74</sup>. After injury to a brain circuit, these mechanisms would be an important means to prevent the development of over-active neural networks. Under most circumstances, this is successful: even after severe brain injury, the majority of patients do not develop epilepsy<sup>75</sup>. One reason that some patients develop epilepsy may be that the mechanisms underlying neuronal homeostasis fail to prevent the development of a seizure-prone network<sup>76, 58</sup>.

While there is substantial empirical data supporting the idea of neuronal homeostasis, the molecular mechanisms are not well understood<sup>74</sup>. Presumably the wiring and re-wiring of neuronal circuits are governed by neuronal homeostasis. Just as neurons may change their complement of voltage-gated membrane proteins to maintain firing after deafferentation, the formation and weighting of new synapses after injury to inputs may be driven by similar mechanisms. Because these mechanisms of neuronal homeostasis are unknown, we don't know how, or if, seizures impact neuronal homeostasis. Although ictal activity levels are high, the rarity and brevity of seizures may reduce their impact on the feedback mechanisms governing synaptic homeostasis. For example, a daily seizure lasting 1 minute may be a catastrophe for the patient, but implies an ictal duty cycle of less than 0.1%. The duration of epochs of activity necessary to influence neuronal homeostasis are not known. If the epileptic circuit is significantly deafferented as a consequence of injury or dysgenesis, such that inter-ictal activity is too low, it may be that the overall activity level of the epileptic circuit (including seizures and epochs of postictal depression) averages to a level that is within the "acceptable" range of the homeostatic mechanisms. Or it may be that ictal hyperactivity and the characteristic postictal depression average to an acceptable level of activity, and the processes that regulate neuronal homeostasis average the two periods together. Epilepsy might also arise from defects in the homeostatic mechanisms, for example an inability to assign an appropriately negative weight to synaptic solutions that result in seizures.

Because we don't have a good idea as to what intracellular signaling networks regulate neuronal activity levels, genetic epilepsies may provide our best clues as to what some of the necessary elements of this network might be. Many of the genes whose mutations are linked to epilepsy are involved in intracellular signaling, and thus could be involved in neuronal homeostasis (Ran et al. 2014).

## Neuronal homeostasis gone awry

A second approach to deciphering molecular mechanisms of neuronal homeostasis is to consider genes for channels that must be exquisitely regulated in order to maintain normal neuronal excitability. The concept of neuronal homeostasis was first derived by considering the consequences of transient pharmacological derangement of voltage-gated sodium channels and ligand-gated GABA<sub>A</sub> channels<sup>77</sup>. Are there genetic "experiments of nature" that correspond to these ideas? Dravet syndrome was mentioned earlier as an early epileptic

encephalopathy resulting from mutations in genes encoding ion channels, most commonly SCN1A gene encoding Nav1.1 sodium channels<sup>11</sup> although causal genes may also include presynaptic proteins and ligand-gated GABA<sub>A</sub> channels<sup>78</sup>.

Loss of function mutations in sodium channel genes would be expected to underlie disorders of sensation, movement, and cognition rather than epilepsy. However, a wide range of loss-of-function mutations in sodium channels result in epilepsy. As discussed earlier, a clever proposed pathogenesis is that fast-firing inhibitory interneurons are disproportionately affected by some of these mutations, and substantial experimental data support this idea<sup>11</sup>. However, why loss of a single allele is sufficient to cause disease is not known; at a molecular level, there is no evidence that the truncated protein exerts a dominant negative effect in experimental models<sup>79</sup>. This raises the possibility that the mutation alters the expression of sodium channels in the cytoplasmic membrane by interference with the feedback mechanism neurons use to sense and adjust the sodium current density. There is some evidence for such a mechanism, in that sodium currents are elevated in iPSC-derived neurons bearing human sodium channel mutations, although the developmental stage at which currents were measured was still very far from mature and the sodium current density was much lower than in the mature animal<sup>80</sup>(Liu et al. 2013). Nevertheless this experiment raises the possibility that haploinsufficiency is not the core problem, but rather dysregulation of sodium current density that results in higher currents at some developmental stages, and lower currents at others. This modulation of intrinsic excitability, along with the circuit alterations discussed earlier, are key elements of neuronal homeostasis<sup>74</sup>. It is possible that careful consideration of the molecular pathogenesis of epilepsies such as Dravet Syndrome will provide important clues to the nature of the mechanisms of neuronal homeostasis, as well as the means by which they may be altered in some genetic forms of epilepsy.

### The variety of etiologies of epilepsies

At the time of the last major review of the molecular mechanisms of epileptogenesis, the number of genes known to cause epilepsy was 13, and all of these genes coded for ion channels<sup>68</sup>. This was prior to the era of rapid, inexpensive gene sequencing, so the predominance of ion channels was in retrospect a function of what genes were being sequenced. Unbiased sequencing and copy number studies have uncovered over 400 genes closely associated with epilepsy<sup>13</sup>. Many of these are discussed in the chapter on the genetics of epilepsy. The bulk of the mutations associated with epilepsy are not in inhibitory or excitatory ion channels, so the mechanisms by which mutations lead to seizures and epilepsy need to be broadened. It is possible that entirely new mechanisms of epilepsy will be discovered as a consequence of investigations into the cell biology of these newly-discovered gene defects. However, it can also be argued that we will find instead a wider variety of means of engendering the core mechanism of episodic, self-reinforcing shifts in the balance of excitation and inhibition. In this scenario, new genes will be found to act, both singly and in concert with other factors, to influence network structure in a way that leads to episodic disinhibition and seizures. For example, there are many factors that determine the stability of network connectivity, including the survival of neurons, that may be linked to epilepsy. As an example, the intractable epilepsies associated with neurodegenerative diseases<sup>81</sup> such as the neuronal ceroid lipofuscinoses<sup>82</sup> can be most



readily explained as network instabilities engendered by loss of connectivity, including loss of neurons. Thus the molecular mechanisms of the epilepsies may be considered as a diverse set of pathways leading to a final common pathophysiology of a self-reinforcing cycle of activity-dependent disinhibition.

These genetic “experiments of nature” have provided us with a wide variety of pathways to epilepsy. Where does that leave neuroscientists doing “experiments of the laboratory”? The positive feedback mechanisms that underlie the distinctive timing features of seizures can now be approached by network studies made possible by new technologies in microscopy, activity-dependent biomarkers, optogenetics, and computation. The timing of seizures is also ripe for study with improvements in electrode technology, telemetry, signal analysis, and seizure detection. Finally, every gene discovered has a complex cellular biology that will take some time to unravel. With luck, the large numbers of discovered genetic mutations can be exploited to develop categories of genetic etiologies. Those categories in turn may be very helpful in focusing our pathophysiological investigations. I will not try to guess those categories at this stage of gene discovery, but I look forward to the point where categorization becomes feasible.

## References


1. Matsumoto H, Ajmonemarsan C. Cellular mechanisms in experimental epileptic seizures. *Science*. Apr 10; 1964 144(3615):193–4. [PubMed: 14107481]
2. Prince DA, Wilder BJ. Control mechanisms in cortical epileptogenic foci. “Surround” inhibition. *Arch Neurol*. Feb; 1967 16(2):194–202. [PubMed: 6018049]
3. Walther H, Lambert JD, Jones RS, Heinemann U, Hamon B. Epileptiform activity in combined slices of the hippocampus, subiculum and entorhinal cortex during perfusion with low magnesium medium. *Neurosci Lett*. Aug 29; 1986 69(2):156–61. [PubMed: 3763042]
4. Wiechert P, Herbst A. Provocation of cerebral seizures by derangement of the natural balance between glutamic acid and gamma-aminobutyric acid. *J Neurochem*. Feb; 1966 13(2):59–64. [PubMed: 5936153]
5. Croucher MJ, Collins JF, Meldrum BS. Anticonvulsant action of excitatory amino acid antagonists. *Science*. May 21; 1982 216(4548):899–901. [PubMed: 7079744]
6. Scharfman HE. The neurobiology of epilepsy. *Curr Neurol Neurosci Rep*. Jul; 2007 7(4):348–54. [PubMed: 17618543]
7. Jett DA. Chemical toxins that cause seizures. *Neurotoxicology*. Dec; 2012 33(6):1473–5. [PubMed: 23085523]
8. Boison D. Methylxanthines, seizures, and excitotoxicity. *Handb Exp Pharmacol*. 2011; 200:251–66. [PubMed: 20859799]
9. Moran NF, Poole K, Bell G, Solomon J, Kendall S, McCarthy M, McCormick D, Nashef L, Sander J, Shorvon SD. Epilepsy in the United Kingdom: seizure frequency and severity, anti-epileptic drug utilization and impact on life in 1652 people with epilepsy. *Seizure*. Sep; 2004 13(6):425–33. [PubMed: 15276147]
10. Macdonald RL, Kang JQ. mRNA surveillance and endoplasmic reticulum quality control processes alter biogenesis of mutant GABAA receptor subunits associated with genetic epilepsies. *Epilepsia*. Dec; 2012 53(Suppl 9):59–70. [PubMed: 23216579]
11. Yu FH, Mantegazza M, Westenbroek RE, Robbins CA, Kalume F, Burton KA, Spain WJ, McKnight GS, Scheuer T, Catterall WA. Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. *Nat Neurosci*. Sep; 2006 9(9):1142–9. [PubMed: 16921370]
12. Carvill GL, Weckhuysen S, McMahon JM, Hartmann C, Møller RS, Hjalgrim H, Cook J, Geraghty E, O’Roak BJ, Petrou S, Clarke A, Gill D, Sadleir LG, Muhle H, von Spiczak S, Nikanorova M,

- Hodgson BL, Gazina EV, Suls A, Shendure J, Dibbens LM, De Jonghe P, Helbig I, Berkovic SF, Scheffer IE, Mefford HC. GABRA1 and STXBP1: novel genetic causes of Dravet syndrome. *Neurology*. Apr 8; 2014 82(14):1245–53. [PubMed: 24623842]
13. Ran X, Li J, Shao Q, Chen H, Lin Z, Sun ZS, Wu J. EpilepsyGene: a genetic resource for genes and mutations related to epilepsy. *Nucleic Acids Res*. Oct 16.2014 PMID: 25324312.
  14. Epi4K Consortium; Epilepsy Phenome/Genome Project. Allen AS, et al. De novo mutations in epileptic encephalopathies. *Nature*. Sep 12; 2013 501(7466):217–21. [PubMed: 23934111]
  15. Veeramah KR, Johnstone L, Karafet TM, Wolf D, Sprissler R, Salogiannis J, Barth-Maron A, Greenberg ME, Stuhlmann T, Weinert S, Jentsch TJ, Pazzi M, Restifo LL, Talwar D, Erickson RP, Hammer MF. Exome sequencing reveals new causal mutations in children with epileptic encephalopathies. *Epilepsia*. Jul; 2013 54(7):1270–81. [PubMed: 23647072]
  16. Weckhuysen S, et al. KCNQ2 Study Group. Extending the KCNQ2 encephalopathy spectrum: clinical and neuroimaging findings in 17 patients. *Neurology*. Nov 5; 2013 81(19):1697–703. [PubMed: 24107868]
  17. Zhang W, Yamawaki R, Wen X, Uhl J, Diaz J, Prince DA, Buckmaster PS. Surviving hilar somatostatin interneurons enlarge, sprout axons, and form new synapses with granule cells in a mouse model of temporal lobe epilepsy. *J Neurosci*. Nov 11; 2009 29(45):14247–56. [PubMed: 19906972]
  18. Buckmaster PS. Does mossy fiber sprouting give rise to the epileptic state? *Adv Exp Med Biol*. 2014; 813:161–8. [PubMed: 25012375]
  19. Sutula TP, Dudek FE. Unmasking recurrent excitation generated by mossy fiber sprouting in the epileptic dentate gyrus: an emergent property of a complex system. *Prog Brain Res*. 2007; 163:541–63. [PubMed: 17765737]
  20. Ferini-Strambi L, Sansoni V, Combi R. Nocturnal frontal lobe epilepsy and the acetylcholine receptor. *Neurologist*. Nov; 2012 18(6):343–9. [PubMed: 23114665]
  21. Herzog AG. Catamenial epilepsy: definition, prevalence pathophysiology and treatment. *Seizure*. Mar; 2008 17(2):151–9. [PubMed: 18164632]
  22. Lopes da Silva F, Blanes W, Kalitzin SN, Parra J, Suffczynski P, Velis DN. Epilepsies as dynamical diseases of brain systems: basic models of the transition between normal and epileptic activity. *Epilepsia*. 2003; 44(Suppl 12):72–83. [PubMed: 14641563]
  23. Jirsa VK, Stacey WC, Quilichini PP, Ivanov AI, Bernard C. On the nature of seizure dynamics. *Brain*. Aug; 2014 137(Pt 8):2210–30. [PubMed: 24919973]
  24. Bracci E, Vreugdenhil M, Hack SP, Jefferys JG. Dynamic modulation of excitation and inhibition during stimulation at gamma and beta frequencies in the CA1 hippocampal region. *J Neurophysiol*. Jun; 2001 85(6):2412–22. [PubMed: 11387387]
  25. Patenaude C, Massicotte G, Lacaille JC. Cell-type specific GABA synaptic transmission and activity-dependent plasticity in rat hippocampal stratum radiatum interneurons. *Eur J Neurosci*. Jul; 2005 22(1):179–88. [PubMed: 16029207]
  26. Wester JC, McBain CJ. Behavioral state-dependent modulation of distinct interneuron subtypes and consequences for circuit function. *Curr Opin Neurobiol*. Jul 22.2014 29C:118–125. [PubMed: 25058112]
  27. Morimoto K, Fahnestock M, Racine RJ. Kindling and status epilepticus models of epilepsy: rewiring the brain. *Prog Neurobiol*. May; 2004 73(1):1–60. [PubMed: 15193778]
  28. Valentine M, Keddie KM, Dunne D. A comparison of techniques in electro-convulsive therapy. *Br J Psychiatry*. Aug; 1968 114(513):989–96. [PubMed: 4879295]
  29. Le Duigou C, Holden T, Kullmann DM. Short- and long-term depression at glutamatergic synapses on hippocampal interneurons by group I mGluR activation. *Neuropharmacology*. Apr; 2011 60(5): 748–56. [PubMed: 21185314]
  30. Jane DE, Lodge D, Collingridge GL. Kainate receptors: pharmacology, function and therapeutic potential. *Neuropharmacology*. Jan; 2009 56(1):90–113. [PubMed: 18793656]
  31. Méndez P, Bacci A. Assortment of GABAergic plasticity in the cortical interneuron melting pot. *Neural Plast*. 2011; 2011:976856. doi: 10.1155/2011/976856. [PubMed: 21785736]
  32. Kaeser PS, Regehr WG. Molecular mechanisms for synchronous, asynchronous, and spontaneous neurotransmitter release. *Annu Rev Physiol*. 2014; 76:333–63. [PubMed: 24274737]

33. Rajakulendran S, Kaski D, Hanna MG. Neuronal P/Q-type calcium channel dysfunction in inherited disorders of the CNS. *Nat Rev Neurol*. Jan 17; 2012 8(2):86–96. [PubMed: 22249839]
34. Lazarevic V, Pothula S, Andres-Alonso M, Fejtova A. Molecular mechanisms driving homeostatic plasticity of neurotransmitter release. *Front Cell Neurosci*. Dec 3.2013 7:244. [PubMed: 24348337]
35. Casillas-Espinosa PM, Powell KL, O'Brien TJ. Regulators of synaptic transmission: roles in the pathogenesis and treatment of epilepsy. *Epilepsia*. Dec; 2012 53(Suppl 9):41–58. [PubMed: 23216578]
36. Meier JC, Semtner M, Winkelmann A, Wolfart J. Presynaptic mechanisms of neuronal plasticity and their role in epilepsy. *Front Cell Neurosci*. Jun 17.2014 8:164. [PubMed: 24987332]
37. Letts VA, Felix R, Biddlecome GH, Arikath J, Mahaffey CL, Valenzuela A, Bartlett FS 2nd, Mori Y, Campbell KP, Frankel WN. The mouse stargazer gene encodes a neuronal Ca<sup>2+</sup>-channel gamma subunit. *Nat Genet*. Aug; 1998 19(4):340–7. [PubMed: 9697694]
38. Yokoi N, Fukata M, Fukata Y. Synaptic plasticity regulated by protein-protein interactions and posttranslational modifications. *Int Rev Cell Mol Biol*. 2012; 297:1–43. [PubMed: 22608556]
39. Fukata Y, Adesnik H, Iwanaga T, Brecht DS, Nicoll RA, Fukata M. Epilepsy-related ligand/receptor complex LGI1 and ADAM22 regulate synaptic transmission. *Science*. Sep 22; 2006 313(5794):1792–5. [PubMed: 16990550]
40. Goodkin HP, Joshi S, Mtchedlishvili Z, Brar J, Kapur J. Subunit-specific trafficking of GABA(A) receptors during status epilepticus. *J Neurosci*. Mar 5; 2008 28(10):2527–38. [PubMed: 18322097]
41. Naylor DE, Liu H, Niquet J, Wasterlain CG. Rapid surface accumulation of NMDA receptors increases glutamatergic excitation during status epilepticus. *Neurobiol Dis*. Jun.2013 54:225–38. [PubMed: 23313318]
42. Kovács R, Rabanus A, Otáhal J, Patzak A, Kardos J, Albus K, Heinemann U, Kann O. Endogenous nitric oxide is a key promoting factor for initiation of seizure-like events in hippocampal and entorhinal cortex slices. *J Neurosci*. Jul 1; 2009 29(26):8565–77. [PubMed: 19571147]
43. Chang P, Walker MC, Williams RS. Seizure-induced reduction in PIP3 levels contributes to seizure-activity and is rescued by valproic acid. *Neurobiol Dis*. Feb.2014 62:296–306. [PubMed: 24148856]
44. Fisher RS, Pedley TA, Moody WJ Jr, Prince DA. The role of extracellular potassium in hippocampal epilepsy. *Arch Neurol*. Feb; 1976 33(2):76–83. [PubMed: 1252153]
45. Staley KJ, Soldo BL, Proctor WR. Ionic mechanisms of neuronal excitation by inhibitory GABA receptors. *Science*. Aug 18; 1995 269(5226):977–81. [PubMed: 7638623]
46. Ransom CB, Ransom BR, Sontheimer H. Activity-dependent extracellular K<sup>+</sup> accumulation in rat optic nerve: the role of glial and axonal Na<sup>+</sup> pumps. *J Physiol*. Feb 1; 2000 522(Pt 3):427–42. [PubMed: 10713967]
47. Raimondo JV, Joyce B, Kay L, Schlagheck T, Newey SE, Srinivas S, Akerman CJ. A genetically-encoded chloride and pH sensor for dissociating ion dynamics in the nervous system. *Front Cell Neurosci*. Nov 13.2013 7:202. [PubMed: 24312004]
48. Deng H, Xiu X, Song Z. The molecular biology of genetic-based epilepsies. *Mol Neurobiol*. Feb; 2014 49(1):352–67. [PubMed: 23934645]
49. Heinemann U, Konnerth A, Pumain R, Wadman WJ. Extracellular calcium and potassium concentration changes in chronic epileptic brain tissue. *Adv Neurol*. 1986; 44:641–61. [PubMed: 3518350]
50. Kovács R, Kardos J, Heinemann U, Kann O. Mitochondrial calcium ion and membrane potential transients follow the pattern of epileptiform discharges in hippocampal slice cultures. *J Neurosci*. Apr 27; 2005 25(17):4260–9. [PubMed: 15858052]
51. Macdonald, RL.; Botzakis, EJ. Physiology and Pathology of chloride transporters and channels in the nervous system. In: Alvarez-Leefmans, F.; Delpire, Eric, editors. *From molecules to diseases*. Elsevier; London UK: 2009.
52. Staley KJ, Proctor WR. Modulation of mammalian dendritic GABA(A) receptor function by the kinetics of Cl<sup>-</sup> and HCO<sub>3</sub><sup>-</sup> transport. *J Physiol*. Sep 15; 1999 519(Pt 3):693–712. [PubMed: 10457084]

53. Kahle KT, Staley KJ, Nahed BV, Gamba G, Hebert SC, Lifton RP, Mount DB. Roles of the cation-chloride cotransporters in neurological disease. *Nat Clin Pract Neurol*. Sep; 2008 4(9):490–503. [PubMed: 18769373]
54. Larsen BR, Assentoft M, Cotrina ML, Hua SZ, Nedergaard M, Kaila K, Voipio J, MacAulay N. Contributions of the Na<sup>+</sup>/K<sup>+</sup>-ATPase, NKCC1, and Kir4.1 to hippocampal K<sup>+</sup> clearance and volume responses. *Glia*. Apr; 2014 62(4):608–22. [PubMed: 24482245]
55. Lillis KP, Kramer MA, Mertz J, Staley KJ, White JA. Pyramidal cells accumulate chloride at seizure onset. *Neurobiol Dis*. Sep; 2012 47(3):358–66. [PubMed: 22677032]
56. Albensi BC, Oliver DR, Toupin J, Odero G. Electrical stimulation protocols for hippocampal synaptic plasticity and neuronal hyper-excitability: are they effective or relevant? *Exp Neurol*. Mar; 2007 204(1):1–13. [PubMed: 17258711]
57. Bertram E. The relevance of kindling for human epilepsy. *Epilepsia*. 2007; 48(Suppl 2):65–74. [PubMed: 17571354]
58. Prince, DA.; Parada, I.; Graber, K. Traumatic Brain Injury and Posttraumatic Epilepsy. In: Noebels, JL.; Avoli, M.; Rogawski, MA.; Olsen, RW.; Delgado-Escueta, AV., editors. *Jasper's Basic Mechanisms of the Epilepsies* [Internet]. 4th edition. National Center for Biotechnology Information (US); Bethesda (MD): 2012.
59. Heinzen EL, et al. ATP1A3 Working Group. Distinct neurological disorders with ATP1A3 mutations. *Lancet Neurol*. May; 2014 13(5):503–14. [PubMed: 24739246]
60. Vaillend C, Mason SE, Cuttle MF, Alger BE. Mechanisms of neuronal hyperexcitability caused by partial inhibition of Na<sup>+</sup>-K<sup>+</sup>-ATPases in the rat CA1 hippocampal region. *J Neurophysiol*. Dec; 2002 88(6):2963–78. [PubMed: 12466422]
61. Guerrini R, Dobyns WB. Malformations of cortical development: clinical features and genetic causes. *Lancet Neurol*. Jul; 2014 13(7):710–26. [PubMed: 24932993]
62. Mirzaa GM, Poduri A. Megalencephaly and hemimegalencephaly: breakthroughs in molecular etiology. *Am J Med Genet C Semin Med Genet*. Jun; 2014 166C(2):156–72. [PubMed: 24888963]
63. Berdichevsky Y, Dryer AM, Saponjian Y, Mahoney MM, Pimentel CA, Lucini CA, Usenovic M, Staley KJ. PI3K-Akt signaling activates mTOR-mediated epileptogenesis in organotypic hippocampal culture model of post-traumatic epilepsy. *J Neurosci*. May 22; 2013 33(21):9056–67. [PubMed: 23699517]
64. Lasarge CL, Danzer SC. Mechanisms regulating neuronal excitability and seizure development following mTOR pathway hyperactivation. *Front Mol Neurosci*. Mar 14.2014 7:18. [PubMed: 24672426]
65. Wong M. A critical review of mTOR inhibitors and epilepsy: from basic science to clinical trials. *Expert Rev Neurother*. Jun; 2013 13(6):657–69. [PubMed: 23739003]
66. Buckmaster PS, Lew FH. Rapamycin suppresses mossy fiber sprouting but not seizure frequency in a mouse model of temporal lobe epilepsy. *J Neurosci*. Feb 9; 2011 31(6):2337–47. [PubMed: 21307269]
67. Gardiner J, Marc J. Disruption of normal cytoskeletal dynamics may play a key role in the pathogenesis of epilepsy. *Neuroscientist*. Feb; 2010 16(1):28–39. [PubMed: 19429889]
68. McNamara JO, Huang YZ, Leonard AS. Molecular signaling mechanisms underlying epileptogenesis. *Sci STKE*. Oct 10.2006 2006(356):re12. [PubMed: 17033045]
69. Fernández E, Rajan N, Bagni C. The FMRP regulon: from targets to disease convergence. *Front Neurosci*. Oct 24.2013 7:191. [PubMed: 24167470]
70. Na ES, Nelson ED, Kavalali ET, Monteggia LM. The impact of MeCP2 loss- or gain-of-function on synaptic plasticity. *Neuropsychopharmacology*. Jan; 2013 38(1):212–9. [PubMed: 22781840]
71. Marsh, ED.; Golden, JA. Developing Models of Aristaless-related homeobox mutations. In: Noebels, JL.; Avoli, M.; Rogawski, MA.; Olsen, RW.; Delgado-Escueta, AV., editors. *Jasper's Basic Mechanisms of the Epilepsies* [Internet]. 4th edition. National Center for Biotechnology Information (US); Bethesda (MD): 2012.
72. Kato M, Dobyns WB. X-linked lissencephaly with abnormal genitalia as a tangential migration disorder causing intractable epilepsy: proposal for a new term, “interneuronopathy”. *J Child Neurol*. Apr; 2005 20(4):392–7. [PubMed: 15921244]

73. Southwell DG, Nicholas CR, Basbaum AI, Stryker MP, Kriegstein AR, Rubenstein JL, Alvarez-Buylla A. Interneurons from embryonic development to cell-based therapy. *Science*. Apr 11.2014 344(6180):1240622. [PubMed: 24723614]
74. O'Leary T, Wyllie DJ. Neuronal homeostasis: time for a change? *J Physiol*. Oct 15; 2011 589(Pt 20):4811–26. [PubMed: 21825033]
75. Frey LC. Epidemiology of posttraumatic epilepsy: a critical review. *Epilepsia*. 2003; 44(Suppl 10): 11–7. [PubMed: 14511389]
76. Volman V, Bazhenov M, Sejnowski TJ. Pattern of trauma determines the threshold for epileptic activity in a model of cortical deafferentation. *Proc Natl Acad Sci U S A*. Sep 13; 2011 108(37): 15402–7. [PubMed: 21896754]
77. Turrigiano GG, Leslie KR, Desai NS, Rutherford LC, Nelson SB. Activity-dependent scaling of quantal amplitude in neocortical neurons. *Nature*. Feb 26; 1998 391(6670):892–6. [PubMed: 9495341]
78. Carvill GL, et al. GRIN2A mutations cause epilepsy-aphasia spectrum disorders. *Nat Genet*. Sep; 2013 45(9):1073–6. [PubMed: 23933818]
79. Ogiwara I, Miyamoto H, Morita N, Atapour N, Mazaki E, Inoue I, Takeuchi T, Itohara S, Yanagawa Y, Obata K, Furuichi T, Hensch TK, Yamakawa K. Nav1.1 localizes to axons of parvalbumin-positive inhibitory interneurons: a circuit basis for epileptic seizures in mice carrying an *Scn1a* gene mutation. *J Neurosci*. May 30; 2007 27(22):5903–14. [PubMed: 17537961]
80. Liu Y, Lopez-Santiago LF, Yuan Y, Jones JM, Zhang H, O'Malley HA, Patino GA, O'Brien JE, Rusconi R, Gupta A, Thompson RC, Natowicz MR, Meisler MH, Isom LL, Parent JM. Dravet syndrome patient-derived neurons suggest a novel epilepsy mechanism. *Ann Neurol*. Jul; 2013 74(1):128–39. [PubMed: 23821540]
81. Girard JM, Turnbull J, Ramachandran N, Minassian BA. Progressive myoclonus epilepsy. *Handb Clin Neurol*. 2013; 113:1731–6. [PubMed: 23622396]
82. Chabrol B, Caillaud C, Minassian B. Neuronal ceroid lipofuscinoses. *Handb Clin Neurol*. 2013; 113:1701–6. [PubMed: 23622391]

**figure.**

Episodic surges in network activity may rarely cross a “seizure threshold” of activity level at which positive feedback mechanisms such as activity-dependent disinhibition dominate network dynamics. The variances of the summed inputs to the epileptic network is proportional to the sum of the input variances, leading to rare surges of the intensity of input. In the case of activity-dependent disinhibition, levels of input above this seizure threshold rapidly degrade inhibition in the epileptic network, leading to further increases network activity. This process culminates in a seizure.